Zydus Cadila, has announced that it was seeking approval from Drug controller General of India (DCGI) for the use of its proprietary Hepatitis C drug as a treatment against the SARS-CoV-2 infection following promising results in Phase 3 trials.
According to the Zydus Statement, the Phase 3 trials demonstrated that a higher proportion of patients in the PegIFN arm showed a two point statistically significant clinical improvement on day 8 as compared to the SOC arm (80.36% vs 68.18%).
Discussing the latest findings, Dr Sharvil Patel, MD at Cadila Healthcare said,“We are encouraged by the results of Phase III study of Pegylated Interferon alpha 2b which has confirmed the potential to reduce virus titres when given earlier in the disease. With Indian Innovation at the forefront helping the country fight the pandemic with diagnostics, vaccines and therapeutics, this marks an important milestone. At Zydus, we stand committed to our endeavor of supporting patients and caregivers with access to treatment options that are affordable and can help in better disease management of COVID 19 at different stages.”
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…